Related papers: Testing Paradox May Explain Increased Observed Pre…

HIV pre-exposure prophylaxis (PrEP) drastically reduces the risk of HIV infection if taken as prescribed, providing almost perfect protection even during unprotected sexual intercourse. Although this has been transformative in reducing new…

Sexual contacts are the main spreading route of HIV. This puts sex workers at higher risk of infection even in populations where HIV prevalence is moderate or low. Alongside condom use, Pre-Exposure Prophylaxis (PrEP) is an effective tool…

Pre-exposure prophylaxis (PrEP) has been established as an effective tool for preventing HIV infection among men who have sex with men (MSM). However, there is the possibility of PrEP usage leading to increased sexual partners and increased…

Pre-exposure prophylaxis (PrEP) consists in the use of an antiretroviral medication to prevent the acquisition of HIV infection by uninfected individuals and has recently demonstrated to be highly efficacious for HIV prevention. We propose…

The government's effort to alleviate HIV stigma has been justified by the suppression effect of stigma on the HIV testing rate. Nevertheless, the deterrence effect of stigma on undesirable sexual behaviours has long been overlooked. This…

The past decade has seen tremendous progress in the development of biomedical agents that are effective as pre-exposure prophylaxis (PrEP) for HIV prevention. To expand the choice of products and delivery methods, new medications and…

Men who have sex with men (MSM) remain disproportionately affected by HIV, yet optimizing Pre-exposure Prophylaxis (PrEP) distribution remains a public health challenge. Current guidelines and most modelling studies do not incorporate…

In the quest for enhanced HIV prevention methods, the advent of antiretroviral drugs as pre-exposure prophylaxis (PrEP) has marked a significant stride forward. However, the ethical challenges in conducting placebo-controlled trials for new…

Pre-exposure prophylaxis (PrEP) is an effective intervention for preventing HIV transmission, but high cost and uneven uptake raise challenges for resource allocation. While spillover effects, wherein PrEP use in one group reduces…

The OraQuick In-Home HIV self-test represents a fast, inexpensive, and convenient method for users to assess their HIV status. If integrated thoughtfully into existing testing practices, accompanied by efficient pathways to formal…

Background: High HIV transmission persists in many U.S. jurisdictions despite prevention efforts. HIV self-testing offers a means to overcome barriers associated with routine laboratory-based testing but carries a risk of increasing…

Anti-retroviral drugs can reduce the infectiousness of people living with HIV by about 96%--treatment as prevention or TasP--and can reduce the risk of being infected by an HIV positive person by about 70%--pre-exposure prophylaxis or…

Cross-sectional incidence estimation based on recency testing has become a widely used tool in HIV research. Recently, this method has gained prominence in HIV prevention trials to estimate the "placebo" incidence that participants might…

The transmission through contacts among MSM (men who have sex with men) is one of the dominating contributors to HIV prevalence in industrialized countries. In Amsterdam, the capital of the Netherlands, the MSM risk group has been traced…

Sexually transmitted infections (STIs) continue to present a complex and costly challenge to public health programs. The preferences and social dynamics of a population can have a large impact on the course of an outbreak as well as the…

Chlamydia trachomatis (Ct) is the most common bacterial sexually transmitted infection (STI) in the United States and is major cause of infertility, pelvic inflammatory disease, and ectopic pregnancy among women. Despite decades of…

With the advent of effective pre-exposure prophylaxis agents, active-controlled HIV prevention trials have become a common study design. Nevertheless, estimating absolute efficacy relative to a placebo remains important. In this paper, we…

Observed gonorrhea case rates (number of positive tests per 100,000 individuals) increased by 75 percent in the United States between 2009 and 2017, predominantly among men. However, testing recommendations by the Centers for Disease…

The development of potent drugs for the control of viraemia in people living with HIV means that infected people may live a normal, healthy life and offers the prospect of eliminating HIV transmission in the short term and HIV infection in…

Background: After a decade of a treatment as prevention (TasP) strategy based on progressive HIV testing scale-up and earlier treatment, a reduction in the estimated number of new infections in men-who-have-sex-with-men (MSM) in England had…